CSIMarket
 
Royalty Pharma Plc  (RPRX)
Other Ticker:  
 
 
Price: $30.0500 $-0.04 -0.133%
Day's High: $30.1988 Week Perf: -0.99 %
Day's Low: $ 29.86 30 Day Perf: 0.07 %
Volume (M): 1,706 52 Wk High: $ 38.19
Volume (M$): $ 51,262 52 Wk Avg: $30.35
Open: $30.14 52 Wk Low: $25.92



 Market Capitalization (Millions $) 13,479
 Shares Outstanding (Millions) 449
 Employees 70
 Revenues (TTM) (Millions $) 2,355
 Net Income (TTM) (Millions $) 1,700
 Cash Flow (TTM) (Millions $) -1,234
 Capital Exp. (TTM) (Millions $) 0

Royalty Pharma Plc
Royalty Pharma Plc is a pharmaceutical company that specializes in acquiring and managing royalty interests in innovative biopharmaceutical products. Established in 1996, the company has since grown to become the largest buyer of biopharmaceutical royalties in the world.

As a business model, Royalty Pharma does not engage in the research, development, or commercialization of new drugs. Instead, the company acquires the rights to receive future royalties from the sale of existing therapies. In doing so, it provides a valuable source of financing for drug developers and manufacturers, while also generating revenue through the collection of these royalties.

The company's portfolio includes approximately 50 different products that are sold around the world. These products are primarily used in the treatment of cancer, immunological disorders, infectious diseases, and rare genetic disorders. Some of the notable products in the Royalty Pharma portfolio include the cancer drug Imbruvica, the HIV therapy Prezcobix, and the cystic fibrosis treatment Kalydeco.

Aside from acquiring and managing royalty interests, Royalty Pharma also invests in the development of new therapies. The company partners with pharmaceutical companies and academic institutions to fund research and development programs that may lead to new, innovative treatments. Thus, Royalty Pharma is a key contributor to the advancement of modern medicine.

Royalty Pharma is headquartered in New York City and has additional offices in London, Dublin, and Jersey City. The company went public in June 2020 and is currently listed on the NASDAQ Stock Exchange under the ticker symbol RPRX. With a market capitalization of over $30 billion, Royalty Pharma is considered one of the largest and most successful pharmaceutical companies in the world.


   Company Address: 110 East 59th Street New York 10022 NY
   Company Phone Number: 883-0200   Stock Exchange / Ticker: NASDAQ RPRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Royalty Pharma Plc

Unexpected Surge in Revenue Sets Royalty Pharma Plc Apart in Fourth Quarter of 2023

Investors in Royalty Pharma Plc have reason to celebrate as the pharmaceutical company has reported positive earnings for the fiscal fourth quarter of 2023. The company saw a significant improvement in earnings per share, which surged by 422.55% compared to the prior reporting season. Additionally, revenue grew by 5.359% to $596.07 million, showcasing the company's solid financial performance.
Furthermore, Royalty Pharma Plc reported earnings of $717.586 million in the fiscal fourth quarter of 2023, a substantial improvement from a net deficit in the same reporting season a year ago. The company also highlighted its improving profit margins, with both net margin and operating margin showing positive growth.

Dividend

Boosting Investor Confidence: Royalty Pharma PLC Growth Portrayed by a 5% Dividend Increase in Q1 2024

Published Fri, Jan 19 2024 1:15 PM UTC


In a move that offers a fresh demonstration of its robust financial health and rewarding commitment to shareholders, global leader in drug royalty acquisitions, Royalty Pharma plc (RPRX), has declared a dividend of $0.21 per Class A share for Q1 2024.
In an official statement released today, the company announced that its board of directors approved the payout, sign...

Royalty Pharma Plc

Profit Plunge: Major Pharmaceutical Company Falters with Earnings Per Share in Q3 2023

The recent financial results of Royalty Pharma Plc for the third quarter of 2023 indicate a decline in various key metrics. The company's income per share dropped by 50% compared to the previous year, while EPS decreased by 68% from the prior reporting period. Additionally, the revenue experienced a significant fall of 6.478% compared to the same period last year, and a slight decrease of 0.351% sequentially.
These disappointing figures demonstrate challenges faced by Royalty Pharma Plc in the third quarter. The drop in income and EPS suggests a decline in profitability, indicating potential issues with the company's operations or market conditions. Furthermore, the decrease in revenue is concerning, especially since the Major Pharmaceutical Preparations industry, as a whole, witnessed revenue growth during the same period.

Dividend

Dividends and Declines: Assessing Royalty Pharma PLC's Stock Performance and Investor Sentiment

Published Mon, Oct 16 2023 8:15 PM UTC



In a recent press release, Royalty Pharma PLC announced the declaration of a dividend for the fourth quarter of 2023. The board of directors approved a dividend payment of $0.20 per Class A ordinary share. This article aims to outline the key facts from the press release and analyze their potential impact on the company's stock performance.
Outlining the Facts:...

Royalty Pharma Plc

Royalty Pharma Plc Reports Revenue Growth Amidst Q2 2023, But Contraction in Earnings Raises Concerns About Profitability and Market Share

Despite a slight increase in revenue of 0.419% in the second quarter of 2023 financial report, Royalty Pharma Plc experienced a significant decline of -28.57% in income compared to the same reporting season a year ago. This decline highlights the challenges faced by the company in maintaining profitability.
Furthermore, the revenue rise of Royalty Pharma Plc was lower than the industry average, which saw a growth of 0.52% during the same period. This suggests potential struggles in capturing market share and maintaining a competitive edge within the Major Pharmaceutical Preparations industry.






 

Royalty Pharma Plc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Royalty Pharma Plc does not provide revenue guidance.

Earnings Outlook
Royalty Pharma Plc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com